Experimental · 5.5/10
CJC-1295
CJC-1295 is a synthetic GHRH analog that stimulates pituitary growth hormone release and downstream IGF-1. The best direct human evidence is small pharmacology work: Teichman 2006 showed sustained GH and IGF-1 increases after DAC CJC-1295, and Ionescu 2006 showed preserved GH pulsatility under continuous stimulation. Body-composition claims mostly borrow from tesamorelin data such as Falutz 2010 and Stanley 2014, not from CJC-1295 outcome trials. Read the full breakdown →
The prediction game
Where does CJC-1295 go in 12 months?
Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Be the first scout on record for CJC-1295. Permanent credit on this page, plus points when your call resolves.
One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
Same as above — one verification covers all your entries here.
For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.